Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

High Response Rate in Heavily Treated Multiple Myeloma With Novel Drug Combination

2.

Measurable Residual Disease Predicts Real-World AML Relapse

3.

Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects

4.

Black women are more likely to die of breast cancer. Close the gap by looking into mammogram studies.

5.

Admissions, medical schools, costs, and eligibility requirements information for FNB Head and Neck Oncology.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot